Compare IDYA & HTGC Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
| Metric | IDYA | HTGC |
|---|---|---|
| Founded | 2015 | 2003 |
| Country | United States | United States |
| Employees | N/A | 50 |
| Industry | Biotechnology: Pharmaceutical Preparations | Investment Managers |
| Sector | Health Care | Finance |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 3.6B | 3.2B |
| IPO Year | 2019 | 2004 |
| Metric | IDYA | HTGC |
|---|---|---|
| Price | $38.85 | $17.46 |
| Analyst Decision | Strong Buy | Buy |
| Analyst Count | 16 | 7 |
| Target Price | ★ $52.86 | $18.86 |
| AVG Volume (30 Days) | 599.8K | ★ 1.3M |
| Earning Date | 05-06-2026 | 05-05-2026 |
| Dividend Yield | N/A | ★ 12.13% |
| EPS Growth | ★ 61.90 | 14.91 |
| EPS | N/A | ★ 0.90 |
| Revenue | ★ $218,710,000.00 | N/A |
| Revenue This Year | N/A | $11.18 |
| Revenue Next Year | $201.05 | $5.24 |
| P/E Ratio | ★ N/A | $19.30 |
| Revenue Growth | ★ 3024.43 | N/A |
| 52 Week Low | $25.36 | $13.70 |
| 52 Week High | $42.68 | $19.25 |
| Indicator | IDYA | HTGC |
|---|---|---|
| Relative Strength Index (RSI) | 52.15 | 53.60 |
| Support Level | $35.11 | $16.37 |
| Resistance Level | $40.58 | $17.93 |
| Average True Range (ATR) | 1.13 | 0.28 |
| MACD | -0.21 | -0.06 |
| Stochastic Oscillator | 36.51 | 31.71 |
IDEAYA Biosciences Inc is an oncology-focused precision medicine company committed to the discovery and development of targeted therapeutics for patient populations selected using molecular diagnostics. Its approach integrates small molecule drug discovery with extensive capabilities in identifying and validating translational biomarkers to develop targeted therapies for select patient populations that are likely to benefit from these targeted therapies. The company's clinical-stage product candidates include darovasertib (PKC), IDE397 (MAT2A), IDE849 (DLL3), IDE275 (Werner Helicase), IDE161 (PARG), and IDE705 (Pol Theta Helicase). In addition, it also working on other development candidates and has multiple earlier-stage preclinical programs.
Hercules Capital Inc is a specialty finance company focused on providing senior secured loans to high-growth, venture capital-backed, and institutional-backed companies in a variety of technology and life sciences industries. The company's primary business objectives are to increase its net income, net investment income, and net asset value (NAV) through its investments mainly in structured debt or senior secured debt instruments of venture capital-backed and institutional-backed companies across a variety of technology-related industries at attractive yields. It finances companies belonging to computer software and hardware, networking systems, semiconductors, medical devices, bio-pharmaceutical, and other related sectors.